Neurodegenerative Disease Market Size Projected To Increase From $62.58 Billion To $88.5 Billion During The Forecast Period
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Neurodegenerative Disease Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The neurodegenerative disease market has experienced notable expansion in recent years, with projections indicating an increase from $57.23 billion in 2025 to $62.59 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.4%. Historically, this growth has been driven by a limited comprehension of disease mechanisms, dependence on traditional symptomatic therapies, an expanding elderly demographic, improved healthcare infrastructure focused on neurology, and restricted access to sophisticated diagnostic technologies.
The neurodegenerative disease market is projected to experience robust growth over the coming years, reaching an estimated $88.5 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.0%. This upward trajectory in the forecast period is fueled by progress in gene and cell therapies, heightened research and development efforts focused on innovative neuroprotective drugs, the broadening of clinical trial networks, the incorporation of artificial intelligence for early detection and ongoing patient monitoring, and a greater emphasis on customized treatment strategies. Key developments shaping this period include a higher incidence of neurodegenerative conditions, intensified financial backing for drug discovery and clinical investigations, the shift toward precise and individualized therapies, enhanced public knowledge and early screening initiatives, and an expansion of care models centered on home-based and outpatient services.
Download A Free Sample Report For Comprehensive Market Insights:
Neurodegenerative Disease Market Growth Factors Supporting Long-Term Expansion
The expansion of research activities and clinical trials is anticipated to drive forward the neurodegenerative disease market in the coming period. Clinical trials are defined as investigations involving human volunteers that assess the safety, effectiveness, and possible adverse effects of novel therapies, pharmaceuticals, or medical devices. This growth in research and clinical trials is largely fueled by a growing need for innovative treatments designed to meet changing healthcare demands and enhance patient outcomes. By generating essential information regarding the safety and efficacy of emerging therapies, clinical trials significantly contribute to neurodegenerative disease research, thereby accelerating therapeutic innovation and improving patient well-being. As an example, a report released in December 2024 by the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, indicated that the number of industry-led clinical trials initiated in the UK increased by 3.7% in 2023 compared to 2022. Consequently, the rise in research and clinical trials is projected to boost the growth of the neurodegenerative disease market.
Neurodegenerative Disease Market Segmentation: How Is The Market Structured Across Key Categories?
The neurodegenerative disease market covered in this report is segmented –
1) By Disease Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Amyotrophic Lateral Sclerosis
2) By Drug Type: N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Acetylcholinesterase (AChE) Inhibitors, Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor, Selective Serotonin Reuptake Inhibitor (SSRIs), Other Drug Types
3) By Route of Administration: Oral, Injectable, Transdermal, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospital, Retail, Online
Subsegments:
1) By Parkinson’s Disease: Idiopathic Parkinson’s Disease, Familial Parkinson’s Disease, Early-Onset Parkinson’s Disease, Parkinsonism
2) By Alzheimer’s Disease: Early-Onset Alzheimer’s Disease, Late-Onset Alzheimer’s Disease, Familial Alzheimer’s Disease (FAD), Inflammatory Subtype, Non-Inflammatory Subtype, Cortical Subtype
3) By Multiple Sclerosis (MS): Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), Progressive-Relapsing MS (PRMS)
4) By Huntington’s Disease: Adult-Onset Huntington’s Disease, Juvenile Huntington’s Disease
5) By Amyotrophic Lateral Sclerosis (ALS): Classical ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS, Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), Juvenile ALS, ALS-Parkinsonism-Dementia Complex (ALS-PDC)
Neurodegenerative Disease Market Industry Trends Shaping Future Revenue Growth
Leading firms within the neurodegenerative disease sector are concentrating on creating cutting-edge solutions, like next-generation adaptive Deep Brain Stimulation (aDBS) devices, designed to boost treatment accuracy, amplify disease-modifying potential, and elevate patient well-being. These modern adaptive deep brain stimulation (aDBS) systems represent sophisticated neurostimulation tools capable of delivering tailored, real-time therapy for Parkinson’s disease through continuous modification of stimulation settings according to neural signals, thereby maximizing therapeutic benefits and reducing adverse effects for enhanced patient health. As an example, in February 2025, Medtronic, a medical technology company from the US, secured clearance from the U.S. Food and Drug Administration (USFDA) for the inaugural adaptive deep brain stimulation (aDBS) system globally, specifically for managing Parkinson’s disease. This authorization covers the premarket approval (PMA) submission for the Percept RC neurostimulator featuring BrainSense technology, which autonomously adjusts treatment based on a patient’s brain activity. Clinically proven to deliver symptom alleviation for individuals with advanced Parkinson’s, this innovation marks a notable breakthrough in customized neuromodulation approaches.
Neurodegenerative Disease Market Competitive Landscape And Leading Companies
Major companies operating in the neurodegenerative disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., AC Immune SA, Amylyx Pharmaceuticals Inc., Sage Therapeutics Inc., Alzheon Inc.
Access The Complete Neurodegenerative Disease Market Report:
Neurodegenerative Disease Market Regional Analysis And Leading Geography
North America was the largest region in the neurodegenerative disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurodegenerative disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
